MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial

por Pott, Christiane, Sehn, Laurie H., Belada, David, Gribben, John, Hoster, Eva, Kahl, Brad, Kehden, Britta, Nicolas-Virelizier, Emmanuelle, Spielewoy, Nathalie, Fingerle-Rowson, Guenter, Harbron, Chris, Mundt, Kirsten, Wassner-Fritsch, Elisabeth, Cheson, Bruce D.
Publicado 2019

Somatic TP53 mutations are preleukemic events in acute lymphoblastic leukemia

por Chitadze, Guranda, Stengel, Anna, John-Klaua, Cathrin, Bruckmüller, Julien, Trautmann, Heiko, Kotrova, Michaela, Darzentas, Franziska, Kelm, Miriam, Pal, Karol, Darzentas, Nikos, Bastian, Lorenz, Kehden, Britta, Wessels, Wiebke, Ströh, Aeint-Steffen, Oberg, Hans-Heinrich, Altrock, Philipp M., Baer, Constance, Meggendorfer, Manja, Gökbuget, Nicola, Baldus, Claudia D., Haferlach, Claudia, Brüggemann, Monika
Publicado 2023